Maribel Salas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/303312/publications.pdf

Version: 2024-02-01

687363 345221 1,344 42 13 36 citations h-index g-index papers 43 43 43 2033 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Confounding by Indication: An Example of Variation in the Use of Epidemiologic Terminology. American Journal of Epidemiology, 1999, 149, 981-983.	3.4	406
2	Culturally Appropriate Storytelling to Improve Blood Pressure. Annals of Internal Medicine, 2011, 154, 77.	3.9	202
3	Impact of Interventions on Medication Adherence and Blood Pressure Control in Patients with Essential Hypertension: A Systematic Review by the ISPOR Medication Adherence and Persistence Special Interest Group. Value in Health, 2013, 16, 863-871.	0.3	125
4	Costs of Medication Nonadherence in Patients with Diabetes Mellitus: A Systematic Review and Critical Analysis of the Literature. Value in Health, 2009, 12, 915-922.	0.3	103
5	Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials. BMC Gastroenterology, 2002, 2, 17.	2.0	63
6	Importance and Challenges of Studying Marketed Drugs: What Is a Phase IV Study? Common Clinical Research Designs, Registries, and Selfâ€Reporting Systems. Journal of Clinical Pharmacology, 2007, 47, 1074-1086.	2.0	58
7	Economic Analysis of Galantamine, a Cholinesterase Inhibitor, in the Treatment of Patients with Mild to Moderate Alzheimer's Disease in The Netherlands. Dementia and Geriatric Cognitive Disorders, 2002, 14, 84-89.	1.5	50
8	Relationship of health behavior theories with self-efficacy among insufficiently active hypertensive African–American women. Patient Education and Counseling, 2008, 72, 137-145.	2.2	41
9	Determinants of On-Scene Time in Injured Patients Treated by Physicians at the Site. Prehospital and Disaster Medicine, 1994, 9, 178-188.	1.3	28
10	Assessing the Health and Economic Impact of Galantamine Treatment in Patients with Alzheimer???s Disease in the Health Care Systems of Different Countries. Drugs and Aging, 2004, 21, 677-686.	2.7	22
11	Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast i»¿cancer patients: a systematic literature review. BMC Cancer, 2021, 21, 967.	2.6	22
12	The relationship between computerized physician order entry and pediatric adverse drug events: a nested matched caseâ€control study. Pharmacoepidemiology and Drug Safety, 2009, 18, 751-755.	1.9	19
13	An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. International Clinical Psychopharmacology, 2016, 31, 134-146.	1.7	16
14	Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K. Cost Effectiveness and Resource Allocation, 2004, 2, 2.	1.5	14
15	Quality of Clinical Documentation and Anticoagulation Control in Patients With Chronic Nonvalvular Atrial Fibrillation in Routine Medical Care. American Journal of Medical Quality, 2007, 22, 327-333.	0.5	14
16	Health-related quality of life in women with breast cancer: a review of measures. BMC Cancer, 2022, 22, 66.	2.6	13
17	Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus. Clinical Therapeutics, 2002, 24, 1690-1705.	2.5	12
18	A Retrospective Study of Comorbidities and Complications in Elderly Acute Myeloid Leukemia Patients in the United States. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e436-e456.	0.4	12

#	Article	IF	CITATIONS
19	Challenges facing drug utilization research in the Latin American region. Pharmacoepidemiology and Drug Safety, 2020, 29, 1353-1363.	1.9	12
20	Less-Than-Standard Treatment in Rectal Cancer Patients: Which Patients Are at Risk?. Journal of the National Medical Association, 2010, 102, 190-198.	0.8	11
21	Analysis of US Food and Drug Administration Warning Letters. Pharmaceutical Medicine, 2008, 22, 119-125.	1.9	10
22	Validated Instruments of Quality of Life (QOL) in Patients With Acute Myeloid Leukemia (AML) and Other Cancers. Frontiers in Pharmacology, 2020, 11, 1109.	3.5	10
23	<p>An Examination of State and Federal Opioid Analgesic and Continuing Education Policies: 2016–2018</p> . Journal of Pain Research, 2020, Volume 13, 2431-2442.	2.0	10
24	Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities. Drug Safety, 2021, 44, 843-852.	3.2	8
25	Turalio risk evaluation and mitigation strategy for treatment of tenosynovial giant cell tumor: framework and experience. Future Oncology, 2022, 18, 1595-1607.	2.4	8
26	Impact of Physical Functioning of Health Status on Hospitalizations, Physician Visits, and Costs in Diabetic Patients. Archives of Medical Research, 2000, 31, 223-227.	3.3	7
27	Gaining Efficiency in Clinical Trials With Cardiac Biomarkers. Journal of the American College of Cardiology, 2021, 77, 1922-1933.	2.8	7
28	Data sources for drug utilization research in Latin American countries—A crossâ€national study: <scp>DASDURâ€LATAM</scp> study. Pharmacoepidemiology and Drug Safety, 2022, 31, 343-352.	1.9	6
29	Modeling the Efficiency of Reaching a Target Intermediate End Point: A Case Study in Type 2 Diabetes in the United States. Value in Health, 2004, 7, 13-21.	0.3	5
30	Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review. PLoS ONE, 2021, 16, e0252925.	2.5	5
31	Cost-effectiveness of oral hypoglycaemic agents for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2005, 6, 601-608.	1.8	4
32	Obesity Modifies the Association of Race/Ethnicity with Medication Adherence in the CARDIA Study. Patient, 2008, 1, 41-54.	2.7	4
33	Frequency of Early Refills for Opioids in the United States. Pain Medicine, 2020, 21, 1818-1824.	1.9	4
34	Managing diabetic foot ulcers: economic consequences in the USA. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 25-32.	1.4	3
35	Review of survival, safety, and clinical outcomes in HER2+ metastatic gastric cancer following the administration of trastuzumabPost-Trastuzumab Gastric Cancer. Cancer Treatment and Research Communications, 2020, 24, 100189.	1.7	3
36	Effect of Cyclosporin Weaning on Glomerular Filtration Rate in Renal Transplantation. Nephron, 1996, 74, 309-312.	0.6	2

#	Article	IF	CITATIONS
37	Evaluation of patient/caregiver and healthcare provider knowledge, attitudes and behavior for safety and use of pexidartinib. Journal of Comparative Effectiveness Research, 2021, 10, 953-967.	1.4	2
38	A qualitative evaluation of patient and healthcare provider knowledge, attitudes, and behavior for safety and use of pexidartinib. Journal of Comparative Effectiveness Research, 2021, 10, 187-192.	1.4	1
39	Data transparency for building a stronger healthcare system: A case study from Argentinean administrative drug utilization data sources. Salud Colectiva, 2021, 17, e3339.	0.2	1
40	Evaluation of patient and healthcare provider (HCP) knowledge, attitudes, and behavior for safety and use of pexidartinib Journal of Clinical Oncology, 2020, 38, e23580-e23580.	1.6	1
41	An Update of the North American Chapter of the International Society of Pharmacovigilance (NASoP). Drug Safety, 2021, 44, 511-513.	3.2	O
42	A retrospective study of comorbidities and complications in elderly acute myeloid leukemia (AML) patients in the U.S Journal of Clinical Oncology, 2018, 36, 7032-7032.	1.6	0